Jeremy K Fox is Associate Professor of Psychology at Montclair State University's College of Humanities and Social Sciences, where he directs the RECAP (Research on Emotion, Coping and Anxiety in Pediatrics) laboratory. His research examines developmental pathways to childhood anxiety and depression. Education includes: PhD in Clinical Psychology, State University of New York at Albany MA in Psychology, State University of New York at Albany BA in Psychology, Johns Hopkins University Research focuses on temperament-environment interactions, emotion regulation deficits, and school-based interventions. Current work investigates parental influences on anxiety development and peer-supported treatment models for minority youth. Articles demonstrate consistent focus on improving mental health service accessibility. Leads graduate training in clinical psychology and mentors doctoral students in anxiety research. RECAP lab investigates affective mechanisms underlying adolescent distress and develops digital interventions for school settings.
Bernadka Dubicka is a Clinical Professor and Honorary Clinical Chair in the Division of Neuroscience at the University of Manchester. She holds dual roles as a research lead at Pennine Care NHS Foundation Trust and as the child and adolescent mental health research lead for Health Innovation Manchester. She is the Editor-in-Chief of the Journal of Child and Adolescent Mental Health and previously served as Chair of the Child and Adolescent Faculty at the Royal College of Psychiatrists (2017–2021). Her academic qualifications include a BSc in Psychology and MBBs from University College London, followed by FRCPsych accreditation in child psychiatry. She earned a gold medal for her MD thesis on behavioral disorder implications in depression. Dubicka’s research focuses on adolescent depression, mood disorders, and brief interventions, including the IMPACT and STADIA trials evaluating psychological treatments and standardized diagnostic assessments. Her work also addresses technology’s role in youth mental health and the eco-crisis’s mental health impacts. Education: BSc Psychology, University College London MBBs, University of London MD Thesis (Gold Medal), University College London FRCPsych, Royal College of Psychiatrists Her research spans depression treatment efficacy, behavioral activation, and cross-national studies on pediatric bipolar disorder. She collaborates internationally and has led over 49 publications. Awards include a gold medal for her thesis and recognition as an RCPsych Fellow. Her work also emphasizes policy advocacy, such as addressing digital rights for children and mental health responses to climate change (e.g., COP26 contributions). She trains clinicians in brief psychosocial interventions and behavioral activation through academic programs and national courses. Grants & Funding: Co-investigator on the £1.1M HTA-funded STADIA trial evaluating remote mental health assessments. Principal investigator on the IMPACT trial, one of the largest adolescent depression trials globally. Labs/Teams: Collaborations include the University of Cambridge (IMPACT trial), University of Nottingham (STADIA), and international taskforces on treatment-resistant depression.
Britt Adamson is an Associate Professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University, where she serves as Director of the Undergraduate Program in Quantitative and Computational Biology. Her lab investigates molecular networks in human cells with focus on stress response mechanisms and genome editing technologies. She received her B.S. in Biology from the Massachusetts Institute of Technology (2005) and Ph.D. in Genetics and Genomics from Harvard University (2012), followed by postdoctoral training at UCSF under Jonathan Weissman supported by a Damon Runyon Cancer Research Foundation Fellowship. Adamson's research centers on how cells organize stress response networks during DNA damage and endoplasmic reticulum stress, developing CRISPR-based functional genomics and single-cell sequencing tools to map molecular behaviors. Her work bridges fundamental cell biology with therapeutic applications in genome editing. Analysis of her 15 most recent publications reveals dominant themes in precision genome editing (prime/base editing optimization) and systematic dissection of DNA repair pathways through combinatorial CRISPR screening. Her lab consistently integrates computational approaches with high-resolution experimental techniques to uncover context-dependent cellular behaviors. Her scientific recognitions include: Damon Runyon Cancer Research Foundation Postdoctoral Fellowship Princeton IP Accelerator Award (2025) STAT Who to Know: 10 Scientists leading a new generation of gene editors (2024) Adamson actively mentors eight graduate students (including alumni Ann Cirincione and Jun Hussmann) and two postdocs, with research funded through institutional awards and collaborative grants. Her lab's technological developments have enabled projects spanning virology, immunology, and developmental biology. The Adamson Lab operates within Princeton's Lewis-Sigler Institute for Integrative Genomics, fostering an interdisciplinary environment that merges cell biology, genomics, and computational science. Current projects focus on improving prime editing efficiency and understanding stress response adaptation in disease contexts.
Dr. Birgit Frauscher is the Lincoln Financial Group Distinguished Professor in Neurobiology at Duke University School of Medicine, where she serves as Professor of Neurology and holds a secondary appointment in the Department of Biomedical Engineering at the Duke Pratt School of Engineering. She is currently the Director of the Duke Comprehensive Epilepsy Center and leads the Analytical Neurophysiology (ANPHY) Lab. Her clinical and research work focuses on epilepsy and sleep medicine, utilizing both invasive and non-invasive electrical recordings to study brain activity in humans. Dr. Frauscher completed her medical training, neurology residency, and subspecialty training in electroencephalography, epilepsy, and sleep medicine at the Medical University of Innsbruck in Austria. After completing her clinical training in 2008, she earned her habilitation degree in 2011. She further specialized in intracranial EEG and signal analysis during a visiting professorship at the Montreal Neurological Institute and Hospital, McGill University (2013-2015), where she later served as an Attending Epileptologist and Group Leader of Epilepsy. Her research interests focus on developing novel seizure-independent EEG markers for the epileptogenic zone, investigating sleep-epilepsy interactions, and using intracranial EEG to study brain physiology during wakefulness and sleep. Her work aims to improve epilepsy diagnosis, prognosis, and treatment outcomes by better localizing the epileptic focus. Dr. Frauscher's recent publications demonstrate her continued leadership in epilepsy research, with over 170 peer-reviewed papers and an H-index of 62. Dr. Frauscher has received several prestigious awards including the Clinician-Scientist awards of the FRSQ (2018-2023), the Michael Prize of the International League against Epilepsy (2019), and the Ernst Niedermeyer Prize from the Austrian Epilepsy Society (2015). Her scholarly work has significantly advanced clinical knowledge in epilepsy and sleep medicine, establishing her as a leading figure in the field. As Director of the Duke Comprehensive Epilepsy Center and head of the ANPHY lab, Dr. Frauscher oversees a research program dedicated to advancing neuroscience through innovative approaches to studying brain activity. Her lab employs quantifiable tools to investigate neurophysiological and pathological processes related to epilepsy and sleep, with the ultimate goal of improving patient outcomes through better understanding of brain function.
Prof. Dr. Nina Gantert is a distinguished Professor of Probability Theory at the Technical University of Munich (TUM) , affiliated with the TUM School of Computation, Information and Technology . She has held faculty positions at Karlsruhe Institute of Technology and the University of Münster prior to joining TUM in 2011. Her research focuses on probability theory , particularly stochastic processes , large deviations , and random media . She investigates random walks in random environments as models for transport in disordered systems and explores applications in physics and biology . Recent publications highlight her work on branching random walks , mixing times , biased random walks , and large deviation principles for complex stochastic systems. She has co-authored studies on random walks in dynamical percolation , interacting edge-reinforced processes , and extremal point processes in branching models. Scientific Awards: Elected fellow of the IMS (2016) Her academic career spans institutions including ETH Zürich, University of Bonn, Technical University of Berlin, and TUM. She has supervised numerous Bachelor’s and Master’s theses on topics ranging from mixing time analysis to percolation theory , often collaborating with international co-authors.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
J. Anthony Movshon is a Professor at New York University (NYU) in the Department of Psychology and a key member of NYU's Center for Neural Science (CNS). His research focuses on the primate visual system, particularly the encoding and decoding of visual information in cortical areas like V1 and MT, and its role in behavior and perception. Education: Doctorate in Visual Neurophysiology and Psychophysics from Cambridge University Research Interests: Movshon investigates the functional architecture of the visual cortex, emphasizing motion, form, and color processing. His work explores how neural activity relates to perceptual decisions and motor behavior, using electrophysiological recordings, neuroimaging, and computational models. He also studies developmental disorders like amblyopia and their impact on visual system organization. Publications: His recent work spans visual texture selectivity in V2, contextual modulation in neural responses, motion processing in MT, and decoding mechanisms in visual cortex. These studies employ interdisciplinary approaches blending neurophysiology, computational neuroscience, and cognitive modeling. Labs & Collaborations: Movshon leads the Visual Neuroscience Laboratory at NYU, collaborating with researchers such as Michael Hawken, Lynne Kiorpes, and Eero Simoncelli.
Susan A. Murphy is the Mallinckrodt Professor of Statistics and of Computer Science at Harvard University, with affiliations to the Kempner Institute. She leads the Statistical Reinforcement Learning Lab, focusing on developing algorithms to inform sequential decision-making in health, particularly for Just-in-Time Adaptive Interventions (JITAIs) and micro-randomized trials (MRTs). Her work is funded by NIH institutes, including NIDA, NHLBI, and NIBIB. Dr. Murphy has been awarded a MacArthur Fellowship (2013) and is a member of the National Academy of Medicine (2014) and the National Academy of Sciences (2016). Her research integrates statistical methods with computer science techniques to optimize mobile health interventions. She collaborates with d3Lab and mDOT on projects like HeartSteps and Sense2Stop, evaluating real-time treatment policies. Notable contributions include advancing MRT designs, sample size calculations, and reinforcement learning algorithms for personalized healthcare. Dr. Murphy advises a large team of postdocs, graduate students, and undergraduates, many of whom hold academic and industry roles globally. She emphasizes engagement in digital interventions, balancing personalization with ethical considerations. Her lab’s work spans algorithm development, clinical trial design, and causal inference, aiming to improve health outcomes through adaptive interventions.
Di Zhu is a Presidential Young Professor in the Department of Materials Science and Engineering at the National University of Singapore (NUS). He holds a B.Eng. from Nanyang Technological University and M.Sc./Ph.D. from MIT, both in Electrical Engineering. His postdoctoral research at Harvard focused on lithium niobate integrated photonics and superconducting detectors. He previously worked as a research scientist and PI at A*STAR's Institute of Materials Research and Engineering (IMRE). Research Interests : Integrated quantum photonics, superconducting detectors, nonlinear optics, and nanofabrication. His group develops scalable quantum photonic devices using lithium niobate and superconducting materials, emphasizing applications in quantum computing, communication, and sensing. Awards : National Research Foundation (NRF) Fellowship Harvard Quantum Initiative (HQI) Postdoctoral Fellowship MIT Jin-Au Kong Thesis Award Advising & Recruitment : Actively recruiting postdocs, PhD students, and interns in areas like integrated photonics, quantum optics, and superconducting detectors. Positions include work on thin-film lithium niobate, quantum simulation, and microwave-optical transduction. Group website: dizhulab.org .
Karin Allor Pfeiffer is a Professor in the Department of Kinesiology at Michigan State University (MSU) and Director of the Institute for the Study of Youth Sports. She holds additional membership in the Center for Physical Activity and Health. With a Ph.D. from MSU, her research focuses on physical activity measurement methodologies and population health interventions, particularly among children and adolescents. Her work addresses obesity prevention, environmental design impacts on activity levels, and sociocultural factors influencing youth sport participation. Education: Ph.D. in Kinesiology from Michigan State University Her research interests emphasize: - Quantitative methods for physical activity assessment - Schoolyard redesign strategies and their health impacts - Cardiometabolic risk factors in pediatric populations - Longitudinal tracking of physical fitness and health outcomes Recent work explores accelerometer fragmentation metrics, GPS-linked activity tracking, and disparities in sedentary behavior across demographic groups. She has pioneered interdisciplinary approaches integrating spatial analysis, wearable technology, and policy evaluation. Key contributions include developing the Observational System for Recording Physical Activity in Children and advancing consensus methods for accelerometer data interpretation. Her studies frequently highlight socioeconomic and environmental determinants of health behaviors. Dr. Pfeiffer collaborates with public health agencies and urban planners to translate research into actionable policies. Her lab focuses on scalable interventions for underserved communities, leveraging community-engaged methods to address greenspace accessibility and safety concerns.
Thomas Perlmann is a Professor in Molecular Developmental Biology at the Karolinska Institutet , leading research at the Department of Cell and Molecular Biology and serving as Director of the Stockholm Branch of the Ludwig Institute for Cancer Research. He also holds the position of Secretary General of the Nobel Assembly and Nobel Committee for Physiology or Medicine since 2016. Ph.D. , Karolinska Institutet, 1991 M.Sc. , Stockholm University, 1987 Research Interests : The Perlmann lab investigates the specification and maintenance of dopamine neurons in the central nervous system, with a focus on transcriptional regulation , signaling pathways , and regenerative medicine applications for Parkinson’s disease and other neurodegenerative disorders. His work bridges developmental biology and neuroscience , emphasizing the role of transcription factors in neuronal identity and function. Recent Research Trends : Perlmann’s recent publications highlight the use of single-cell RNA sequencing to dissect dopamine neuron heterogeneity , epigenetic regulation during development, and transcriptomic changes in Parkinson’s disease models. His studies increasingly leverage multiomics and bioinformatics to map neuronal lineage trajectories and gene expression dynamics. Scientific Awards : Royal Medal by HM the King (2025) Nicholson Lecturer, Rockefeller University (2011) Göran Gustafsson Prize in Molecular Biology (1999) Eric K. Fernström Young Investigator Prize (1997) Advising & Collaborations : While no student names are explicitly listed, Perlmann collaborates extensively with researchers such as Malin Parmar , Agnete Kirkeby , and Per Svenningsson on projects related to neuronal development and cell therapy . His lab receives funding from institutions like the Ludwig Institute for Cancer Research . Labs & Teams : The Perlmann Lab at Karolinska Institutet includes researchers like Linda Gillberg , Laura Lahti , and Behzad Yaghmaeian Salmani , who work on mouse models , single-cell transcriptomics , and bioinformatics to study dopamine neuron biology.
Zakia Hammal is an Assistant Research Professor with dual appointments at Carnegie Mellon University, holding positions in the Robotics Institute within the School of Computer Science and the Department of Biomedical Engineering in the College of Engineering. Her work bridges computer science, machine learning, artificial intelligence, and social/behavioral psychology to advance computational models for human behavior analysis. Dr. Hammal's educational background includes a PhD in Computer Science, a Master of Artificial Intelligence and Algorithmic with specialization in Image Processing, and an Engineer's degree in Computer Science with specialization in Computer Systems. Her academic journey has positioned her at the intersection of technical expertise and healthcare applications. Her research focuses on multimodal human behavior modeling in social interaction, with particular emphasis on health informatics and affective computing (Emotion AI). Dr. Hammal's work has pioneered computational models for multimodal assessment of psychiatric disorders, including depression severity evaluation, automatic pain intensity measurement, assessment of expressiveness in children with facial abnormalities, analysis of non-verbal communication in mother-infant interaction, and identification of behavioral markers in autism spectrum disorder. Her approach integrates computer vision, machine learning, and behavioral psychology to create systems that can objectively measure human behaviors that are often subjective in clinical settings. Analysis of her recent publications reveals a consistent trajectory toward more sophisticated multimodal approaches to healthcare challenges, particularly in pain assessment and mental health diagnostics. Her work increasingly emphasizes interpretable AI models that can translate complex behavioral patterns into clinically meaningful insights, with growing attention to applications for vulnerable populations including infants, elderly patients, and those with craniofacial abnormalities or autism spectrum disorder. Women in AI Awards North America 2023 – AI Researcher of the Year Award Outstanding Reviewer Award at FG 2015 Best Paper award at ACII 2015 Outstanding Paper award at ICMI 2012 Dr. Hammal has secured significant research funding, primarily from the U.S. National Institutes of Health, including an R01 grant for developing a Multimodal Behavioral AI platform for pain assessment and management, and additional grants for automatic pain assessment in older adults with dementia. Her leadership extends to mentoring through her involvement in organizing workshops and conferences that train the next generation of researchers in affective computing and health informatics. As an active leader in her field, Dr. Hammal serves as ACM ICMI Steering Board Committee Member, Associate Editor for IEEE Transactions on Affective Computing and IEEE Transactions on Multimedia, and has organized numerous influential workshops including the International Workshop on Automated Assessment of Pain and Face and Gesture Analysis for Health Informatics. She is set to serve as Program Chair for FG 2025, ACII 2025, and ICMI 2026, demonstrating her growing influence in shaping the future direction of research in multimodal interaction and affective computing.
Wing Lam is an Associate Research Scientist in the Department of Pharmacology at the Yale School of Medicine. He holds a BSc in Molecular Biology and a PhD in Biochemical Pharmacology from City University of Hong Kong, followed by postdoctoral training at Yale. His research focuses on developing traditional Chinese medicine (TCM) formulations as adjuvants for cancer therapy, notably YIV-906, which enhances chemotherapy efficacy and mitigates intestinal toxicity. Lam also pioneered the STAR database for herbal drug discovery and the Mechanism-Based Quality Control (MBQC) platform for botanical drug standardization. Education: BSc (Hons) Molecular Biology, City University of Hong Kong, 1995 PhD Biochemical Pharmacology, City University of Hong Kong, 1999 Postdoc, Pharmacology, Yale University, 1999-2002 His research interests span cancer pharmacology, TCM modernization, and mitochondrial toxicity mechanisms. Key projects include YIV-906’s role in enhancing anti-PD1 and CAR T-cell therapies, developing L-nucleoside analogs like troxacitabine, and investigating tylophorine analogs’ antitumor effects. Lam has co-chaired sessions at multiple Consortium for Globalization of Chinese Medicine (CGCM) meetings and contributed to patents on herbal drug formulations and quality control methods. Recent work explores YIV-906’s potential for inflammatory bowel disease (IBD) and phase II clinical trials for colon and liver cancers. Lam’s publications highlight synergistic drug interactions, mitochondrial DNA depletion mechanisms, and TCM’s evidence-based application in chronic diseases. His grants include studies on PHY906 as an adjuvant in rectal cancer therapy and collaborations with Yiviva, Inc. He maintains active roles in editorial boards, including a special issue on herbal drug quality control in Frontiers in Pharmacology . Lam’s lab is embedded within Dr. Yung-Chi Cheng’s group, focusing on translational pharmacology and botanical drug innovation.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
Itsik Pe'er is a Full Professor and Vice-Chair in the Department of Computer Science at Columbia University's Fu Foundation School of Engineering & Applied Science, and holds a joint appointment as Professor of Systems Biology at the Vagelos College of Physicians and Surgeons. His research focuses on computational methods in human genetics, including genetic variation analysis, disease association studies, and algorithm development for genomic data. He leads the Itsik Pe'er Lab of Computational Genomics, which develops tools like Xplorigin, Germline, and SEACells to address challenges in genomics and medical research. His work spans machine learning applications in healthcare, microbiome analysis, and cancer genomics. Notable contributions include studies on hypertensive disorders in pregnancy, bias correction in predictive models, and the development of non-Euclidean learning libraries like Manify. Pe'er has advised students including Vladimir Vacic, Anat Kreimer, and Arthi Ramachandran, and collaborates on grants addressing genetic epidemiology and computational biology. His lab's location is in the Computer Science Building at Columbia's Morningside Campus.
